TABLE 1.
Summary of 24 adult patients with NF1 diagnosed with glioblastoma, with treatment, recurrence, and survival
| Authors & Year | Age (yrs)/ Sex | Location | Molecular Features | Treatment | Recurrence | Survival (mos) | Functional Status |
|---|---|---|---|---|---|---|---|
| Miaux et al., 199717 |
32/F |
Occipital |
NA |
NA |
NA |
NA |
NA |
| Miyata et al., 200518 |
30/F |
Right frontal |
NA |
SR + RT + chemotherapy (PCV) |
10 mos |
12 mos + |
NA |
| Mehta et al., 200819 |
63/M |
Parietal |
NA |
Biopsy |
NA |
2 mos |
NA |
| Hakan et al., 200820 |
28/F |
Frontal |
NA |
SR + RT + chemotherapy (TMZ) |
NA |
41 mos + |
NA |
| Broekman et al, 200921 |
28/F |
Right cerebellar |
NA |
SR + RT + chemotherapy (TMZ) |
6 mos |
12 mos |
Nystagmus, diplopia, facial numbness, ataxia |
| Theeler et al., 20145 |
59/M |
Right temporal |
NA |
SR + RT + chemotherapy (TMZ) + 17 cycles bevacizumab + irinotecan |
24 mos |
104.4 mos + |
Stable |
| Theeler et al., 20145 |
25/M |
Thalamus |
NA |
RT + chemotherapy (TMZ) + 10 cycles bevacizumab + TMZ |
2 mos |
13.9 mos |
Multiple ischemic strokes, sepsis |
| Theeler et al., 20145 |
32/M |
Cerebellar hemispheres |
IDH wild type |
RT + chemotherapy (TMZ) + adjuvant erlotinib 9 cycles + 37 cycles bevacizumab + irinotecan |
3 mos |
72.6 mos |
Cardiac thrombosis |
| Jeong et al., 20147 |
32/M |
Right frontal |
NA |
SR + RT + chemotherapy (TMZ) |
NA |
9 mos + |
NA |
| Varghese et al., 201522 |
60/M |
Right frontal |
NA |
SR + RT + chemotherapy (TMZ) |
NA |
NA |
Hemiparesis improved |
| Ameratunga et al., 201623 |
24/M |
Left cerebellar |
IDH wild type |
Tumor debulking + RT + chemotherapy (TMZ) + SR + everolimus+ TMZ + MEK inhibitor (trametinib) |
24 mos |
24 mos + |
Improved clinically, functional |
| Shibahara et al., 201824 |
52/M |
Occipital |
NA |
SR + RT + chemotherapy |
NA |
49 mos |
NA |
| Shibahara et al., 201824 |
34/M |
Frontal |
NA |
SR + RT + chemotherapy |
NA |
106 mos + |
NA |
| Shibahara et al., 201824 |
28/M |
Insula |
NA |
SR + RT + chemotherapy |
NA |
60 mos + |
NA |
| Shibahara et al., 201824 |
53/M |
Frontal |
NA |
SR + RT + chemotherapy |
NA |
87 mos + |
NA |
| Singla et al., 201825 |
25/M |
Right frontal |
NA |
SR + RT |
24 mos |
36 mos + |
Back to baseline, functional |
| Fortunato et al., 201826 |
23/M |
Brainstem |
IDH wild type |
SR + RT + chemotherapy (TMZ) |
NA |
1 mos |
Adrenal insufficiency |
| Wong et al., 201927 |
27/M |
Multiple |
IDH1 mutation |
Subtotal resection + RT + chemotherapy (TMZ) |
NA |
39 mos |
NA |
| Narasimhaiah et al., 201916 |
21/F |
Right frontoparietal lobe |
NA |
SR + RT + chemotherapy (TMZ) |
NA |
32 mos + |
NA |
| Narasimhaiah et al., 201916 |
26/M |
Right paraventricular |
NA |
Subtotal resection + total resection 10 years later |
120 mos |
Lost follow up |
NA |
| Flower & Gallo, 201928 |
23/M |
Cerebellar |
NA |
SR + RT + chemotherapy (TMZ) |
17 mos |
18 mos |
Acute neurological decline, memory loss, unsteady gait, dysarthria, and dysphasia |
| Awada et al., 202029 |
19/M |
Brainstem |
IDH 1 mutation |
RT + chemotherapy (TMZ) + VEGF inhibitor (axitinib) + PCDL-1 inhibitor (avelumab) + axitinib + lomustine, 2 cycles + MEK inhibitor (trametinib) |
6 mos |
48 mos + |
Back to baseline, functional |
| Cai et al., 202130 |
51/F |
Right temporal |
IDH wild type |
SR + RT + chemotherapy (TMZ) |
NA |
13 mos + |
Headache and weakness improved, functional |
| Present case | 27/M | Frontoparietal | IDH wild type 1p/19q codeletion |
SR + RT + chemotherapy (TMZ) + bevacizumab + bevacizumab/irinotecan |
48 mos | 121 mos + | Functional |
NA = not available; PCDL-1 = programmed cell death 1 ligand; PVC = procarbazine, nimustine hydrochloride, and vincristine sulfate; RT = radiotherapy; SR = gross total resection; TERT = telomerase reverse transcriptase; TMZ = temozolomide; VEGF = vascular endothelial growth factor.